MedTrace Logo

Prevention of Bleeding in Total Joint Replacement: Combined Route Administration of Tranexamic Acid

NCT05874583 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-05-25

No results posted yet for this study

Summary

The investigators aimed to compare two doses of intravenous (IV) tranexamic acid (TXA) with a combined single dose of topical and IV TXA on haemoglobin decline 24 hours after total joint arthroplasties.

The investigators conducted randomized, double-blind trial. The participants were randomized to either intrvenous group receiving 2 doses of 1 gram TXA in intravenous route 3 hours apart, or a combined application group receiving the first 1 gram IV and the topical dose was 1.5 gram after reduction of the fascia.

Conditions

  • Tranexamic Acid
  • Arthroplasty, Replacement, Knee
  • Blood Transfusion
  • Arthroplasty, Replacement, Hip

Interventions

DRUG

Combined route administration of Tranexamic acid

tranexamic acid in topical route administration

DRUG

Intravenous route Tranexamic acid injection

Intra venous route administration

Sponsors & Collaborators

  • Mongi Slim Hospital

    lead OTHER

Principal Investigators

  • Mhamed Sami MS Mebazaa, Pr · Mongi Slim local research ethical committee

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2022-09-30
Completion
2022-12-31

Countries

  • Tunisia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05874583 on ClinicalTrials.gov